Concepedia

Gemcitabine as a Single Agent in the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Alexander Fosså, Armando Santoro, Wolfgang Hiddemann, Lorenz Truemper, N. Niederle, Sarwat Buksmaui, Gianni Bonadonna, S. Seeber, M. R. Nowrousian

Journal of Clinical Oncology · 1999 · 123 citations · 26 references

DOI

Abstract

The present schedule of gemcitabine displays modest efficacy and mild toxicity in pretreated aggressive NHL.

References

26

Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

Thierry Philip, Cesare Guglielmi, Anton Hagenbeek et al. · New England Journal of Medicine · 1995 · 2.4K citations

Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

William Plunkett, Peng Huang, Yi-Zheng Xu et al. · PubMed · 1995 · 756 citations

Gemcitabine: preclinical pharmacology and mechanisms of action.

William Plunkett, Peng Huang, C. E. Searcy et al. · PubMed · 1996 · 395 citations

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

R Ohno, Kosuke Okada, T Masaoka et al. · Journal of Clinical Oncology · 1990 · 229 citations

, , +15

Gemcitabine in the Treatment of Refractory Hodgkin’s Disease: Results of a Multicenter Phase II Study

Armando Santoro, Henning Bredenfeld, Liliana Devizzi et al. · Journal of Clinical Oncology · 2000 · 228 citations